Stockscreener 앱 받기
16.41
0.31%
0.05
시장 영업 전:
16.44
0.03
+0.18%
전일 마감가:
$16.36
열려 있는:
$16.51
하루 거래량:
2.55M
Relative Volume:
0.87
시가총액:
$51.84B
수익:
$29.85B
순이익/손실:
$776.90M
주가수익비율:
68.15
EPS:
0.2408
순현금흐름:
$4.35B
1주 성능:
-3.81%
1개월 성능:
-8.38%
6개월 성능:
+16.38%
1년 성능:
+8.25%
1일 변동 폭
$16.34
$16.55
1주일 범위
$16.34
$16.88
52주 변동 폭
$12.99
$18.89
다케다약품공업 ADR Stock (TAK) Company Profile
명칭
Takeda Pharmaceutical Co Adr
전화
-
주소
-
Compare TAK vs ZTS, HLN, TEVA, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TAK
Takeda Pharmaceutical Co Adr
|
16.41 | 51.84B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
116.65 | 49.05B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.47 | 42.09B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.62 | 36.82B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
569.11 | 24.94B | 3.18B | 1.33B | 1.04B | 27.90 |
다케다약품공업 ADR Stock (TAK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-08 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2026-01-13 | 재개 | Morgan Stanley | Overweight |
| 2025-04-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2023-03-16 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-07-19 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2021-10-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-19 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-11-01 | 개시 | Cowen | Market Perform |
| 2019-08-15 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
모두보기
다케다약품공업 ADR 주식(TAK)의 최신 뉴스
Takeda Pharmaceutical Co Ltd stock (JP3730800003): Is its rare disease focus strong enough to unlock - AD HOC NEWS
Takeda Pharmaceutical Co Ltd (HAM:TKDA) Stock News, Headlines & Updates - GuruFocus
Takeda Pharmaceutical Co Ltd Stock Baskets - GuruFocus
TAK Stock Price, Quote & Chart | TAKEDA PHARMACEUTIC-SP ADR (NYSE:TAK) - ChartMill
Polycythemia Vera Market Set for Transformation: Key 9 Companies Expected to Enter by 2036 | DelveInsight - GlobeNewswire Inc.
Takeda Pharmaceutical (ADR) stock (US8740602052): Why Google Discover changes matter more now - AD HOC NEWS
Takeda Pharmaceutical Co Ltd (HAM:TKDA) Competitors 2026 - GuruFocus
Takeda Pharmaceutical Co Ltd Stock Operating Data - GuruFocus
Takeda Pharmaceutical Co Ltd stock: What you should know now for smart investing - AD HOC NEWS
Takeda Exits Dementia Drug Partnership With Denali Therapeutics - Benzinga
Takeda Pharmaceutical Company Limited (TAK) stock price, news, quote and history - Yahoo Finance Singapore
Takeda Pharmaceutical Company Limited (TAK) Stock Price, News, Quote & History - Yahoo! Finance Canada
Takeda Pharmaceutical Co Ltd (HAM:TKDA) Stock HoldersInstitutional & Insider Ownership - GuruFocus
Takeda Pharmaceutical (ADR) Stock: A Stable Global Pharma Play with Focus on Oncology and Rare Disea - AD HOC NEWS
Who's Buying or Selling Takeda Pharmaceutical Co Ltd (HAM:TKDA) Stock Today? - gurufocus.com
Takeda Pharmaceutical Co Ltd Stock Intrinsic Values | HAM:TKDA - GuruFocus
Takeda Pharmaceutical Co Ltd Stock Historical Valuations | HAM:TKDA - GuruFocus
Takeda Pharmaceutical Co Ltd (LTS:0A87) Bonds - GuruFocus
Takeda Pharmaceutical stock faces pressure from geopolitical risks amid pipeline advances - AD HOC NEWS
Takeda Pharmaceutical (ADR) stock faces pressure amid pipeline setbacks and competitive oncology cha - AD HOC NEWS
Takeda Pharmaceutical (ADR) Stock Steady Amid Pharma Sector Volatility as Investors Eye Pipeline Pro - AD HOC NEWS
Takeda Pharmaceutical Co Ltd (HAM:TKDA)Valuation Measures & Financial Statistics - GuruFocus
FDA Grants Priority Review for Takeda (TAK) and Protagonist's Rusfertide in PV Treatment - Finviz
DNLI Q4 Loss Narrower Than Expected, Hunter Syndrome Drug in Focus - Finviz
Takeda Stock: Quiet Japan Pharma With a Big U.S. Pipeline Bet - AD HOC NEWS
Takeda Stock: Quiet Pharma Giant That US Investors Keep Missing - AD HOC NEWS
Takeda Pharmaceutical ADR sees IBD RS rating climb to 76 - MSN
Should Investors Buy, Sell or Hold KROS Stock Ahead of Q4 Earnings? - Finviz
FedEx Upgraded, Costco Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Earnings call transcript: Takeda beats Q3 2025 forecasts, stock climbs - Investing.com
Takeda Pharmaceutical ADR: Defensive Pharma Giant Tests Investor Patience as Shares Drift Near Lows - AD HOC NEWS
Is Takeda Pharmaceutical Company Limited (TAK) One of the Best Healthcare Stocks to Buy for 2026? - Finviz
Argenx SE – ADR (ARGX) Sentiments Bolstered on Vyvgart FDA Priority Review Milestone - Yahoo Finance
Takeda Pharma ADR earnings beat by $0.04, revenue topped estimates - Investing.com Australia
Stocks To Watch: Takeda Pharmaceutical ADR Sees Relative Strength Rating Rise To 83 - Investor's Business Daily
Takeda Q3 FY2025 slides: Revenue dips 3.3% as company preps key 2026 launches - Investing.com
Earnings call transcript: Takeda Pharma Q3 2026 sees mixed performance - Investing.com
다케다약품공업 ADR (TAK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.04%
1.15%
자본화:
|
볼륨(24시간):